T he microcirculation, which includes small arteries, arterioles, and capillaries, represents a key network in the support of adequate tissue perfusion and metabolism. The tone of resistance vessels has a crucial role in dissipating the pulsatile energy generated by the heart's contraction, thus protecting small capillaries from pressure damage. This energy dissipation is achieved at the cost of an increase in peripheral vascular resistance, making the regulation of the vascular tone at this level one of the most important determinants of blood pressure values (1) . Accordingly, vascular dysfunction, which characterizes several pathological conditions, largely involves adaptive changes at this vascular bed.
The endothelium is a fundamental tissue that guarantees vascular homeostasis through opposing action of substances with vasodilating/antithrombogenic properties and vasoconstricting/prothrombotic activities (2) . In healthy conditions, the most important compound generated by endothelial cells and influencing vascular homeostasis is nitric oxide (NO). This is a gas produced by the constitutive endothelial enzyme NO synthase (eNOS) under the influence of chemical or mechanical forces. Among these, the most characterized are the activities of endothelial agonists (e.g., acetylcholine, bradykinin) acting on specific endothelial receptors and the shear stress (3) . NO exerts its cardiovascular (CV) protective role by relaxing smooth muscle cell media, inhibiting platelet adhesion and aggregation, and preventing leukocyte adhesion and migration into the arterial wall, muscle cell proliferation, and adhesion molecule expression (2, 3) .
In the presence of major CV risk factors, endothelium loses its protective role, switching to a proatherosclerotic phenotype. This condition, called "endothelial dysfunction," is characterized by either a reduced production of NO or a predominant vascular generation of vasoconstricting and proatherosclerotic substances, generically termed endothelium-derived contracting factors (4) . These include reactive oxygen species (ROS), mainly superoxide, that are generated by different intracellular sources according to clinical conditions and vascular districts, including nicotinamide dinucleotide phosphate (NADPH) oxidase, cyclooxygenase, xanthine oxidase, and the mitochondria (5, 6) . Superoxide rapidly reacts with NO to form the highly reactive intermediate peroxynitrite that in turn determines vascular changes limiting NO bioavailability. Superoxide may also stimulate the expression of endothelin-1 (ET-1), another endothelium-derived contracting factor that binds to specific receptors on both endothelial and smooth muscle cells (ET A and ET B ), mediating the vast majority of its biological effects (6, 7) .
Recently, a key role played by low-grade vascular inflammation on endothelial dysfunction and atherosclerosis emerged (8, 9) . In particular, TNF-a has been suggested as a key cytokine involved in reducing NO availability, an effect exerted by both inducing ROS generation and directly inhibiting eNOS activity (8) .
Obesity is a complex chronic disease associated with increased CV morbidity and mortality (10) . The earliest manifestation of CV disease in obesity is endothelial dysfunction, an alteration that has been documented in several different vascular beds (11) (12) (13) (14) (15) . A condition of chronic lowgrade inflammation secondary to the abnormal production of proinflammatory cytokines, including TNF-a (16, 17) , is considered the main mechanisms leading to endothelial dysfunction in obesity. This is a brief overview of the known mechanisms involved in endothelial dysfunction pathogenesis in the microcirculation of patients with obesity, along with addressing the complex links among visceral adiposity, TNF-a, and microcirculation.
Obesity and Endothelial Dysfunction
To date, some experimental and human studies have homogeneously documented the presence of endothelial dysfunction in obesity (18, 19) . A large body of literature indicates that obesity is responsible for directly detrimental effects on the vasculature, independent from the concomitant presence of traditional CV risk factors commonly detected in obesity, including hypertension, diabetes mellitus, or dyslipidemia. The first demonstration that obesity per se can cause endothelial dysfunction was reported by Steinberg et al. (11) , who documented reduced endothelium-dependent vasodilation to methacholine in the leg microcirculation of patients with obesity. In line with these results, Perticone et al. identified a linear relationship between severity of obesity and reduction of endothelial function in the forearm microcirculation of patients who are overweight/obese (13) . Importantly, in this study, the intra-arterial infusion of ascorbic acid ameliorated the response to acetylcholine, suggesting a role for oxidative stress in mediating endothelial dysfunction. Similarly, de Jongh et al. (20) demonstrated by iontophoresis technique that small cutaneous vessels of women with obesity have a reduced vasodilating response to acetylcholine, but not to sodium nitroprusside, compared with healthy controls; this alteration was detectable in both basal conditions and during hyperinsulinemia. In this study, vascular response to acetylcholine was directly related to insulin sensitivity and inversely related to blood pressure values, suggesting that reduced endothelial function might contribute to the development of microangiopathy associated with obesity and insulin resistance in this vascular bed. A growing amount of literature also investigated endothelial function in resistance vessels isolated from a biopsy of abdominal subcutaneous tissue or visceral fat of patients with severe obesity through an in vitro/ex vivo technique. These studies concordantly documented a dramatic reduction of endothelium-dependent relaxation of small resistance arteries from patients with obesity compared with lean controls (14, 15, 21) . In particular, the blunted response to acetylcholine was resistant to the eNOS inhibitor N v -nitro-L-arginine methyl ester (L-NAME), and potentiated by the antioxidant Tempol, which also restored the inhibitory effect of L-NAME on the endothelial agonist (15) . These findings demonstrate that oxidative stress might have a greater influence on NO availability in such vascular beds than does the intrinsic activity of the eNOS. More recently, the presence of an independent effect of obesity on microcirculation was further confirmed by van der Heijden et al. (22) . The authors showed that, in patients with treated metabolic risk factors and suspected coronary artery disease, body mass index was significantly associated with decreased endothelium-dependent vasodilatation measured with peripheral arterial tonometry and laser Doppler flowmetry. Notably, this relationship remained highly important even after adjustment for confounding risk factors, including diabetes mellitus, hypertension, hypercholesterolemia, and smoking.
In conclusion, concordant findings emerging from several vascular beds and subsequent to different endothelial stimuli demonstrate that microvascular circulation represents a major target for obesity-related endothelial dysfunction. In isolated resistance vessels, in which the mechanisms accounting for endothelial dysfunction have been explored, a blunted activity of NO secondary to oxidant excess was demonstrated.
Obesity and inflammation: the role of perivascular adipose tissue
Over the past decade, a fundamental breakthrough in obesity-related CV disease was that obesity is associated with a chronic, low-grade, systemic inflammatory exposure. Although multiple pathways could account for the elevated inflammatory burden detected in obesity, adipose tissue is emerging as a central source of proinflammatory cytokine production. This affirmation was proposed by Hotamisligil et al. (23) , showing that TNF-a was constitutively expressed by adipose tissue, overexpressed in obesity, and acted as a potential mediator of insulin resistance in several animal models. From this pioneering observation, many studies confirmed that human obesity is an inflammatory disease; this observation also provided important insights into the mechanisms underlying chronic activation of the immuneinflammatory response in patients with obesity. It has been documented that circulating mononuclear cells and inflammatory cells infiltrating the adipose tissue of patients with obesity adopt a proinflammatory phenotype (24) , which is characterized by an elevated and dysregulated production of proinflammatory cytokines. Beyond the contribution of immune-inflammatory cells, the visceral fat is increasingly recognized as a major source of proinflammatory chemokines, named adipokines. The generation of adipokines by fat cells can be regarded as an endocrine function and makes adipose tissue the largest endocrine organ of the body, particularly in patients affected by severe obesity. Major adipokines generated by fat cells include leptin, resistin, and adiponectin (25) , all of which can influence, through several mechanisms, vascular homeostasis. Leptin is the main protein produced by adipocytes, and its blood concentration is proportional to the amount of adipose tissue. In vitro studies suggested that leptin could cause an increment of oxidative stress production in endothelial cells (26) . Moreover, leptin can stimulate the secretion of TNF-a and interleukin-6 (IL-6) which, in turn, may induce endothelial dysfunction (27) . Other reports, conversely, suggested that leptin might induce vasorelaxation, an effect that appeared to be mediated by mechanisms involving the production of the endothelium-derived hyperpolarizing factor (28, 29) . The ability of leptin to stimulate vasodilation by NO-independent or NOdependent mechanisms however, requires, further investigation, because available evidence is conflicting. For example, although Matsuda et al. (30) showed a NOindependent vasorelaxation of human coronary arteries after infusion of leptin, Tsuda et al. (31) documented an influence of NO-dependent pathways on the endothelial vasorelaxation obtained with leptin.
Resistin, produced by adipogenesis, is involved in the development of insulin resistance and obesity (32) . It was recently observed that endothelial cells incubated with human recombinant resistin increase their production of ET-1 and expression of adhesion molecules (33), a finding suggesting a direct effect of resistin on vascular endothelium. Most of the convincing evidence on the effects of adipokines on the vascular wall involves the role of adiponectin. This adipokine, produced in mature adipocytes, has an opposite effect from leptin and resistin. Indeed, adiponectin stimulates insulin sensitivity (34) , reduces the expression of adhesion molecules on the endothelium, inhibits the transformation of macrophages into foam cells, and reduces the smooth muscle cells proliferation. A study including hypertensive patients documented that circulating levels of adiponectin are inversely related to the severity of the endothelial dysfunction measured at the level of forearm microcirculation (35) . Obesity is characterized by reduced production and activity of adiponectin (36) , potentially reducing the protective effects of this adipokine against the development of endothelial dysfunction and the atherosclerotic process.
A major mechanism whereby obesity can induce vascular changes involves the PVAT, which exerts deleterious effects on the vasculature by secreting TNF-a and IL-6 (37). Experimental reports indicated TNF-a might stimulate ROS production via activation of NAD (P)H oxidase (38) or by the activation of nuclear transcription factor-k B (NF-kB) (39) . This leads to mobilization and activation of macrophages, migration and proliferation of smooth muscle cells, and induction of adhesion molecule expression by the endothelial and smooth muscle cells of the vascular wall (40) . IL-6 can increase the ROS production by activating xanthine oxidase and NAD(P)H oxidase. IL-6 also stimulates liver synthesis of C-reactive protein, which reduces NO production by decreasing the expression of eNOS (41) . An increased expression of TNF-a and the acquisition of a pro-oxidant phenotype by PVAT might represent common mechanisms leading to vascular changes in condition of insulin resistance. Indeed, PVAT from a rodent model of metabolic syndrome shows an increased TNF-a generation, together with a decreased adiponectin expression, a greater NADPH oxidase activity and a reduced expression of antioxidant •O2
2 dismutase (-1, -2, and -3) (42).
In humans, many studies contribute to our understanding a possible link between TNF-a and obesity-related vascular dysfunction. In patients with obesity-related metabolic syndrome, Tesauro et al. (43) assessed the effects of TNF-a neutralization by infliximab, a monoclonal antibody blocking the TNF-a signaling, on vascular reactivity during hyperinsulinemia. At baseline, patients showed a reduced relaxation to both acetylcholine and sodium nitroprusside during hyperinsulinemia, compared with control subjects. Infliximab potentiated the vascular responses to both agonists. Of note, the antioxidant ascorbic acid improved the vasodilator response to acetylcholine in patients with obesity, with no further potentiating effect when infliximab was concomitantly administrated. These results indicate that TNF-a inhibition may ameliorate vascular reactivity in patients with obesity during hyperinsulinemia, an effect consequent to a decreased oxidative stress (43) .
More recently, an interesting study conducted in isolated resistance vessels evidenced a specific role of PVAT-derived inflammation in the pathogenesis of vascular dysfunction. Small arteries with and without PVAT were obtained from a subcutaneous gluteal fat biopsy of obese and control subjects. Although PVAT was able to generate factors that potentiated NO availability in vessels of lean controls, in subjects with obesity, which showed an increased area of adipocytes, the presence of PVAT did not improve vasodilation (44) . Acute injection of TNF-a and IL-6 around healthy blood vessels reduced dilator activity of PVAT, resulting in no longer differences compared with the obese group. Preincubation of ROS scavengers or cytokine antagonist was able to prevent these alterations (44) . Taken together, these results evidence that in physiological conditions adipocytes contribute to the regulation of local vascular tone by modulating NO availability. Adipocyte hypertrophy, oxidant excess, and an increased accumulation of TNF-a in the PVAT of subjects with obesity result in a loss of this important regulation. These data highlight the pivotal role of inflammation as a promoter of vascular dysfunction, being an important mechanism whereby the pathological adipose tissue exerts a deleterious effect on the surrounding vasculature in a paracrine manner.
Does vasculature represent a mere target of PVAT-derived TNF-a?
Based on current evidence, therefore, PVAT is emerging as a direct regulator of vascular tone throughout the generation of proinflammatory cytokines with documented direct deleterious effects on the vasculature, including TNF-a. These data strengthen the concept of obesity as an inflammatory state and indicate vasculature as a potential target of adipose tissue-derived inflammatory cytokines. However, whether low-grade inflammation result also from the generation of proinflammatory products at the level of the vasculature, as well as their possible effects on vascular endothelial function in human obesity remain to be elucidated. A recent study conducted in our laboratory attempted to respond to these uncertainties. Small arteries were isolated from visceral fat immediately after collection of a biopsy sample during laparoscopic surgery, in patients with and without severe obesity. Vessels from the obese group showed a reduced endothelium-dependent relaxation, which was resistant to L-NAME. This blunted relaxation was reversed by the superoxide scavenger Tempol and, to a similar extent, by infliximab (15) . These data were corroborated by the direct measure of the vascular wall superoxide anion concentration performed at the confocal microscope after staining with the fluorescent probe dihydroethidium. Vessels from the obese group showed higher levels of superoxide anions compared with the nonobese group, which was dramatically reduced by incubation with Tempol or infliximab. Immunohistochemistry indicated a marked up-regulation of TNF-a mainly in the media layer of these vessels, demonstrating that the vascular wall may also be a source of TNF-a involved in endothelial dysfunction. Taken together, these results demonstrate that small vessels from patients with obesity show a reduced NO availability secondary to excess ROS generation and that TNF-a promotes endothelial dysfunction by stimulating intravascular ROS generation. In the same study, we explored the potential pathway(s) involved in TNF-a-induced vascular ROS generation, focusing on the role of NAD(P)H oxidase, inducible nitric oxide synthase (iNOS) and xanthine oxidase. Using the specific inhibitors of these enzymes (apocynin, S-methylisothiourea and allopurinol), we found that only the inhibition of NAD(P)H oxidase and iNOS, but xanthine oxidase, could restore the impaired endothelial function in the obese group. Similarly, the inhibition of NAD(P)H oxidase and iNOS led to a substantial reduction of the intravascular superoxide generation as assessed by dihydroethidium. Comprehensively, these results suggest that NAD(P)H oxidase and iNOS are the two major enzymatic pathways mediating the increase of vascular wall oxidative stress induced by TNF-a in obesity (15) .
Role of insulin and insulin resistance status on vascular inflammation
In the past two decades, much evidence has suggested that insulin might have an important role in regulating vascular homeostasis, over and above the control of local and systemic metabolism. It is now recognized that insulin has vasodilatory effects on arteries, veins, and microcirculation (45) (46) (47) . Several studies convincingly documented that such effects are mainly mediated by an increased stimulation and expression of eNOS within endothelial cells, which results in an increased NO availability (48, 49) . In addition to its direct effect on eNOS, insulin might influence NO availability also by controlling systemic and local levels of inflammation and oxidative stress. The expression of the key proinflammatory transcription factor NF-kB is suppressed by insulin, particularly within the endothelial cell, and this leads to a reduced vascular inflammation (50) (51) (52) . Insulin also suppresses ROS generation by inhibiting the NADPH oxidase activity (51) . Based on these findings, it is not surprising that conditions of insulin resistance (such as in human obesity) lead to ROS generation, vascular inflammation, and inhibition of eNOS expression (53). TNF-a has an important role in promoting vascular inflammation and oxidative stress because of altered vascular activity of insulin because it can reduce the insulin signal by inhibiting the expression of the insulin receptors (54) . Thus, beyond its direct effects, the TNF-a might also influence the vascular homeostasis of patients with obesity by reducing the insulin signal and its anti-inflammatory and antioxidative effects on the vascular wall.
Additional support to the presence of a strong relationship between inflammation, insulin resistance, and vascular changes in obesity is provided by the evidence that an excessive macronutrient intake, primary cause of an excessive body weight, results in an increase in ROS generation and inflammatory response (52, 55) , as well as increment in plasma endotoxin concentrations and the expression of Toll-like receptors (56) . Long-term caloric restriction and diet-induced weight loss, by contrast, result in the fall of proinflammatory cytokines, including TNF-a, and this is accompanied by a reduced insulin release after glucose challenge (16, 17) . Similarly, the reduced inflammation and insulin resistance that follow bariatric surgery (57) are associated with a fall in the circulating levels of molecules with a negative effect on vascular homeostasis, including ET-1, elements of the renin-angiotensin system, and neprilysin (58) .
Local inflammation in obesity: the role of ET-1
In healthy conditions, ET-1 participates to the vascular homeostasis by binding with two receptor subtypes, ET A and ET B . ET A receptors are represented on smooth muscle cells only, mediate contractions, and promote growth. In contrast, ET B receptors are located on smooth muscle cells (where they evoke contractions) and on endothelial cells (where they induce relaxation stimulating NO production). Although in physiological condition the NO counterbalances the contracting effect of ET-1 (7, 59) , in obesity a vascular ET-1/NO imbalance is commonly detected. Indeed, Cardillo et al. (60) observed that intra-arterial infusion of an ET A receptor blocker (BQ-123) resulted in substantial vasodilation in forearm microcirculation from subjects who are overweight and obese, but not in lean hypertensive subjects or normotensive control subjects irrespective of their body mass. The BQ-123-induced vasodilation was significantly related to body mass in hypertensive subjects but not in control subjects, thereby indicating a selective enhancement of ET A -dependent vasoconstrictor tone in hypertensive patients with increased body mass (60) . These findings suggest a potential role of the activated ET-1 system in the pathophysiology of complications of obesity-related hypertension. The upregulated production of ET-1 in obesity might result from the activation of various vascular pathways. Among these, experimental evidence indicated that oxidative stress is one of the most important factors stimulating the increase of ET-1 synthesis in human coronary artery smooth muscle cells. In turn, ET-1 signal is able to stimulate ROS production in the vascular wall, potentially creating a vicious cycle.
The evidence obtained by Amiri et al. (61, 62) in transgenic mice with endothelium-targeted overexpression of human preproET-1 strengthened the hypothesis of a positive feedback loop between ET-1 signal and oxidative stress. In this model, preproET-1 overexpression causes remodeling and inflammation of resistance vessels in the absence of a blood pressure elevation, an effect mediated by multiple mechanisms, including the activation of vascular NAD(P)H oxidase. The increased production of ET-1 under conditions of increased vascular oxidative stress also raises the hypothesis that local inflammation might interfere with the ET-1-mediated vascular tone in obesity. Oxidant excess can be hypothesized as a mechanism whereby TNF-a interferes with the ET-1/NO system. Such a possibility was recently addressed in our laboratory. We aimed to evaluate whether TNF-a contributes to the vasoconstriction induced by endogenous ET-1 in small arteries isolated from visceral abdominal fat of patients with severe obesity, and whether this effect might be indirectly mediated by a modulation of tonic NO release. Endogenous ET-1 activity was assessed by the ET A blocker BQ-123, whereas the anti-TNF-a infliximab and L-NAME were used to test TNF-a and NO, respectively. The obese group showed a blunted L-NAME-induced vasoconstriction, which was improved by preincubation with infliximab. Also, BQ-123 induced a greater relaxation in the obese group, which was unaffected by L-NAME but attenuated by infliximab. Of note, PVAT removal reversed these effects. Incubation of the vessel with the NAD(P)H oxidase inhibitor apocynin, L-NAME, or BQ-123 induced a substantial reduction of the superoxide excess within the vascular wall of patients with obesity; a similar effect was obtained when the TNF-a signaling was blocked with infliximab (63) . We also detected an increased vascular expression of ET-1, ET A , and ET B receptors and higher vascular/perivascular TNF-a and TNF-a receptor expression (63) . These complex results provided evidence that, in small arteries from patients with obesity, the ET-1/NO imbalance is mediated by vascular and perivascular TNF-a excess, coupled with an increased vascular expression of ET-1 and ET A receptor. Such alterations induce endothelial dysfunction, which is characterized by ROS excess and impair tonic NO release in the vascular wall. These findings also support the concept that, in obesity, PVAT loses its vascular protective properties, switching toward a functionally active procontractile inflammation source.
Conclusions
Obesity is characterized by a marked endothelial dysfunction caused by a reduced NO availability. In this clinical condition, PVAT plays a crucial role in generating proinflammatory cytokines, including TNF-a, with a documented direct deleterious effect toward the vasculature. In particular, although TNF-a promotes superoxide generation in the vascular wall via different pathways, the most important contribution might be due to the hyperactivation of NAD(P)H oxidase. In such a scenario, crucial roles are played by the insulin resistance status and chronic macronutrient intake, which contribute to obesity-associated chronic inflammatory status. TNF-a also participates in the ET-1/NO imbalance in small arteries from patients with obesity ( Fig. 1) . At present, the available literature does not enable establishing whether the small arteries and adipocytes located within PVAT should be regarded as independent and coexisting sites of TNF-a generation or, by contrast, whether there is a hierarchical relationship or mutual interplay between these two body areas. Any extrapolation of the potential effects of visceral fat on the small vessels to other vascular beds requires caution because vascular responses to autocrine/paracrine functions of the endothelium can vary depending on the anatomical location of blood vessels. Nevertheless, there is no doubt that these findings recognize obesity as an inflammatory condition and identify the microvasculature from visceral fat an important source of low-grade inflammation and Figure 1 . The hypothetic mechanisms whereby TNF-a induces vascular changes in small vessels from patients with obesity. In visceral obesity, chronic low-grade vascular inflammation generated by PVAT and/or within vasculature stimulates ROS generation through NAD(P)H oxidase activation and other sources, which in turn reduces NO availability. TNF-a also directly stimulates ET-1 generation, which exerts a mutual stimulation with ROS.
oxidative stress that, together with the PVAT, directly contribute to the local development of insulin resistance.
